As the first-in-class DLL3 BiTE, tarlatamab recruits T cells to DLL3-expressing tumors, triggering MHC-I-independent activation, granzyme/perforin release, and tumor lysis (26, 76). The gene discussed is DLL3; the disease is neoplasm.